Compare GFI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFI | ZTS |
|---|---|---|
| Founded | 1887 | 1952 |
| Country | South Africa | United States |
| Employees | 6560 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4B | 48.7B |
| IPO Year | N/A | 2012 |
| Metric | GFI | ZTS |
|---|---|---|
| Price | $46.37 | $121.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $45.71 | ★ $156.20 |
| AVG Volume (30 Days) | 2.6M | ★ 3.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.12% | 1.75% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | N/A | ★ 6.02 |
| Revenue | N/A | ★ $9,467,000,000.00 |
| Revenue This Year | $38.35 | $5.69 |
| Revenue Next Year | N/A | $4.81 |
| P/E Ratio | $25.02 | ★ $20.19 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $19.41 | $114.47 |
| 52 Week High | $61.52 | $172.23 |
| Indicator | GFI | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.09 | 46.41 |
| Support Level | $37.19 | $117.42 |
| Resistance Level | $47.39 | $130.52 |
| Average True Range (ATR) | 2.06 | 3.20 |
| MACD | -0.99 | -0.75 |
| Stochastic Oscillator | 7.27 | 40.38 |
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.